Cargando…

Advances in Nanoparticles for Effective Delivery of RNA Therapeutics

RNA therapeutics, including messenger RNA (mRNA) and small interfering RNA (siRNA), are genetic materials that mediate the translation of genetic direction from genes to induce or inhibit specific protein production. Although the interest in RNA therapeutics is rising globally, the absence of an eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Min Ji, Lim, Jaesung, Kim, Se-Na, Park, Dae-Hwan, Kim, Tae-Hyung, Park, Wooram, Park, Chun Gwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean BioChip Society (KBCS) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891745/
https://www.ncbi.nlm.nih.gov/pubmed/35261724
http://dx.doi.org/10.1007/s13206-022-00052-5
_version_ 1784661964549521408
author Byun, Min Ji
Lim, Jaesung
Kim, Se-Na
Park, Dae-Hwan
Kim, Tae-Hyung
Park, Wooram
Park, Chun Gwon
author_facet Byun, Min Ji
Lim, Jaesung
Kim, Se-Na
Park, Dae-Hwan
Kim, Tae-Hyung
Park, Wooram
Park, Chun Gwon
author_sort Byun, Min Ji
collection PubMed
description RNA therapeutics, including messenger RNA (mRNA) and small interfering RNA (siRNA), are genetic materials that mediate the translation of genetic direction from genes to induce or inhibit specific protein production. Although the interest in RNA therapeutics is rising globally, the absence of an effective delivery system is an obstacle to the clinical application of RNA therapeutics. Additionally, immunogenicity, short duration of protein expression, unwanted enzymatic degradation, and insufficient cellular uptake could limit the therapeutic efficacy of RNA therapeutics. In this regard, novel platforms based on nanoparticles are crucial for delivering RNAs to the targeted site to increase efficiency without toxicity. In this review, the most recent status of nanoparticles as RNA delivery vectors, with a focus on polymeric nanoparticles, peptide-derived nanoparticles, inorganic nanoparticles, and hybrid nanoparticles, is discussed. These nanoparticular platforms can be utilized for safe and effective RNA delivery to augment therapeutic effects. Ultimately, RNA therapeutics encapsulated in nanoparticle-based carriers will be used to treat many diseases and save lives.
format Online
Article
Text
id pubmed-8891745
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean BioChip Society (KBCS)
record_format MEDLINE/PubMed
spelling pubmed-88917452022-03-04 Advances in Nanoparticles for Effective Delivery of RNA Therapeutics Byun, Min Ji Lim, Jaesung Kim, Se-Na Park, Dae-Hwan Kim, Tae-Hyung Park, Wooram Park, Chun Gwon Biochip J Review Article RNA therapeutics, including messenger RNA (mRNA) and small interfering RNA (siRNA), are genetic materials that mediate the translation of genetic direction from genes to induce or inhibit specific protein production. Although the interest in RNA therapeutics is rising globally, the absence of an effective delivery system is an obstacle to the clinical application of RNA therapeutics. Additionally, immunogenicity, short duration of protein expression, unwanted enzymatic degradation, and insufficient cellular uptake could limit the therapeutic efficacy of RNA therapeutics. In this regard, novel platforms based on nanoparticles are crucial for delivering RNAs to the targeted site to increase efficiency without toxicity. In this review, the most recent status of nanoparticles as RNA delivery vectors, with a focus on polymeric nanoparticles, peptide-derived nanoparticles, inorganic nanoparticles, and hybrid nanoparticles, is discussed. These nanoparticular platforms can be utilized for safe and effective RNA delivery to augment therapeutic effects. Ultimately, RNA therapeutics encapsulated in nanoparticle-based carriers will be used to treat many diseases and save lives. The Korean BioChip Society (KBCS) 2022-03-03 2022 /pmc/articles/PMC8891745/ /pubmed/35261724 http://dx.doi.org/10.1007/s13206-022-00052-5 Text en © The Korean BioChip Society 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Byun, Min Ji
Lim, Jaesung
Kim, Se-Na
Park, Dae-Hwan
Kim, Tae-Hyung
Park, Wooram
Park, Chun Gwon
Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
title Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
title_full Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
title_fullStr Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
title_full_unstemmed Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
title_short Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
title_sort advances in nanoparticles for effective delivery of rna therapeutics
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891745/
https://www.ncbi.nlm.nih.gov/pubmed/35261724
http://dx.doi.org/10.1007/s13206-022-00052-5
work_keys_str_mv AT byunminji advancesinnanoparticlesforeffectivedeliveryofrnatherapeutics
AT limjaesung advancesinnanoparticlesforeffectivedeliveryofrnatherapeutics
AT kimsena advancesinnanoparticlesforeffectivedeliveryofrnatherapeutics
AT parkdaehwan advancesinnanoparticlesforeffectivedeliveryofrnatherapeutics
AT kimtaehyung advancesinnanoparticlesforeffectivedeliveryofrnatherapeutics
AT parkwooram advancesinnanoparticlesforeffectivedeliveryofrnatherapeutics
AT parkchungwon advancesinnanoparticlesforeffectivedeliveryofrnatherapeutics